NTRC has launched an expansion of its Oncolines™ cancer cell line panel, from 66 to 102 cell lines. Oncolines™ are proliferation assays on a panel of genetically well-characterized cancer cell lines from diverse tumour tissue origin. NTRC has a commercial license from the American Type Culture Collection (ATCC). Oncolines™ profiling includes genomic biomarker analysis and comparative profiling against a library of more than 150 pre-profiled anti-cancer agents. In recent publications from NTRC in Molecular Cancer Therapeutics [1] and from the University of Basel (Switzerland) in Nature Communications [2] the reproducibility of Oncolines™ cell panel profiling and its application in mechanism-of-action studies has been demonstrated. Bayer Pharma A.G. (Berlin, Germany) recently presented Oncolines™ results at the American Association of Cancer Research (AACR) conference in Washington D.C. (USA) [3]. The Oncolines™ biomarker analysis can be extended with gene expression analysis through GeneNominator™.

Characteristics Oncolines™:

  • Readout ATPlite™
  • Low passage number and ATCC recommended culturing conditions
  • No IC50 extrapolation
  • 384-well, automated liquid handling
  • Manual inspection of curves

Recent publications with Oncolines™ and OncolinesProfiler™ results:

[1] Uitdehaag et al. (2016) Cell panel profiling reveals conserved therapeutic clusters and differentiates the mechanism of action of different PI3K/mTOR, Aurora kinase and EZH2 inhibitors. Molecular Cancer Therapeutics 15, 3097-3109

[2] Bohnacker et al. (2017) Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention. Nature Communications 8:14683

[3] Politz et al. (2017) Preclinical activity of the FGFR inhibitor rogaratinib (BAY 1163877) alone or in combination with antihormonal therapy in breast cancer. AACR Annual Conference Abstract 1079.

For more information or quotations, please sent an e-mail to services@ntrc.nl.